Small Pharmaceuticals
Market Cap
₹6,758 ₹6,758 Cr.
P/E
53.48
PEG
1.53
PEG = P/E ÷ 5yr Forward EPS CAGR
5yr Forward EPS CAGR Thesis - Base Case

- The thesis lives on ANDA launch cadence and Apnar scaling; if Apnar misses quarterly revenue thresholds or launches slip below five per year, the bear case becomes primary.- Bull case depends on Amerisyn federal contracts and Apnar exceeding targets, while bear case is driven by Apnar delays plus US tariff escalation and ANDA slippage.

Key Ratios

Debt to Equity
Debt to Equity
0.35
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
15.47 %
Institutions
Institutions
16.39 %
Market cap
Market cap
6,758 Cr
No. of Shareholders
No. of Shareholders
36,498
OPM (%)
OPM (%)
29.60 %
PE
PE
53.48
Prom Holding
Prom Holding
45.82 %
ROCE (%)
ROCE (%)
15.61
ROE (%)
ROE (%)
12.36
Sales
Sales
691 Cr
  • Senores Pharmaceutic
  • Ajanta Pharma
  • Alembic Pharma
Last updated on 11 Sep 2026
  • Senores Pharmaceuticals makes generic medicines for the US, Canada, the UK and emerging markets. It sells its own ANDAs and makes products for partners. It also sells APIs and branded generics in India.
  • Earnings come from regulated-market ANDAs. Own products are about 55% of regulated sales and rising. About 60-70% of US sales use government and controlled-substance channels.
  • It operates two USFDA-approved plants and one WHO-GMP plant. It has five to seven year US agreements with Alkem, Sun Pharma and others.
  • It is adding Apnar lines and API capacity. It is building own-label and government sales. FY27 capex is ₹100-120 Cr, cut from ₹200 Cr.
  • Working capital is high at 187 days, partly from pre-revenue Apnar stocking. Unbilled revenue of ₹172 Cr reflects the profit-share model.
  • Near-term profit in this ramp depends on Apnar reaching ₹100-120 Cr and new ANDA launches. Management guides 30-40% revenue and 50-60% PAT growth for FY27.
  • It has grown fast by buying companies and ANDAs. Delays in integrating them or launching products could hurt growth and margins.
  • Apnar inspection closure Within stipulated timeframe
    It confirms the September inspection outcome with no GMP observation.
  • Apnar balance 25% stake Q2FY27
    It completes ownership of the Vadodara plant.
  • Zoraya and Amerisyn go-live Sep-Oct 2026
    Own-label sales and federal government sales begin.
  • Chhatral PIC/S approval Q2-Q3 FY27
    It opens EU access for 100-120 products to file.
  • API greenfield 169 MTPA was CY2026; no update since 6 Sep 2026
    It adds 169 MTPA of API capacity for backward integration.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
662
52W Range
High
1600
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

7 Yes

Positive for this company

2 Neutral

Neutral for this company

7 No

Negative for this company

1 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

    Select a Metric
    • Number of ANDA's Approved (.)
    • R&D as a % of Total Sales (%)

    Peer Comparison

    FAQs on Senores Pharmaceuticals Ltd. Business

    Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms.

    Senores Pharmaceutic major competitors are Ajanta Pharma, Alembic Pharma, Caplin Point Labs., Gland Pharma, Strides Pharma Scien, Innova Captab, Sun Pharma Adv. Res.
    Market Cap of Senores Pharmaceutic is ₹6,654 Crs.
    While the median market cap of its peers are ₹15,785 Crs.

    Senores Pharmaceutic seems to be less financially stable compared to its competitors.
    Altman Z score of Senores Pharmaceutic is 7.83 and is ranked 5 out of its 8 competitors.

    Company Filing

    2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Jan May Jul May Jul Nov Dec
    Investor Presentation Jan May Jul May Jul Nov Dec
    Conference Call Jan Aug Mar Jun Nov Dec
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material